Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Sur...
June 07 2021 - 09:00AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage
biopharmaceutical company seeking to discover and develop
innovative medicines in oncology and infectious disease with a
current focus on breast cancer and COVID-19, announces that it will
hold a webinar at 8 am Pacific Time on June 9, 2021 to release and
discuss final data from its Phase 2 study of Endoxifen administered
to breast cancer patients prior to surgery. The webinar will be
attended by Dr. Steven Quay, CEO and President, Kyle Guse, CFO and
General Counsel, and Dr. B. Heather Fraser, VP Clinical, Regulatory
and CMC.
To register to join the complimentary ZOOM-based webinar event,
please visit Tribe Public LLC at ATOS.TribePublic.com.
Registered participants may email questions for Atossa’s management
to Tribe Public prior to the event at research@tribepublic.com
or share their questions via the ZOOM chat feature during the
event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will
host the event and relay questions to management.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to discover and develop innovative medicines in
oncology and infectious diseases with a current focus on breast
cancer and COVID-19. For more information, please visit
www.atossatherapeutics.com.
About Tribe Public LLC
Tribe Public LLC is a San Francisco, CA-based organization that
hosts complimentary worldwide webinar & meeting events in the
U.S. Tribe's events focus on issues that the Tribe's members care
about with an emphasis on hosting management teams and experts from
publicly traded companies from all sectors & financial
organizations that are seeking to increase awareness of their
products, progress, and plans. Tribe members primarily include
Institutions, Family Offices, Portfolio Managers, Registered
Investment Advisors, Accredited Investors, Sell Side Analysts, and
members of media. Tribe Members are encouraged to express their
interest in speakers at the Tribe Public website via the Tribe's
FREE "Wish List" process. Visit Tribe Public's
Website http://www.tribepublic.com/ to join the Tribe and
express your interests today.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
interim and final clinical results, actions and inactions by the
FDA, the outcome or timing of regulatory approvals needed by Atossa
including those needed to commence studies of AT-H201, AT-301 and
Endoxifen, lower than anticipated rate of patient enrollment,
estimated market size of drugs under development, the safety and
efficacy of Atossa’s products, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others such as patent rights, whether
reduction in Ki-67 or any other result from a neoadjuvant study is
an approvable endpoint for oral Endoxifen, and other risks detailed
from time to time in Atossa’s filings with the Securities and
Exchange Commission, including without limitation its periodic
reports on Form 10-K and 10-Q, each as amended and supplemented
from time to time.
Company Contact: Atossa Therapeutics, Inc. Kyle Guse CFO and
General Counsel Office: (866) 893-4927 kyle.guse@atossainc.com
Investor Relations Contact: Core IROffice: (516)
222-2560ir@atossainc.com
Source: Atossa Therapeutics, Inc.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2023 to Mar 2024